SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Biotech / MedicalOcular Sciences (OCLR)


Previous 10 Next 10 
To: EyeDrMike who wrote (4)5/20/1999 6:11:00 PM
From: Alan Villalon
   of 36
 
From what I read, looks like the recall will be less than $200K. I also saw that there was only 3 complaints that management reported off.

Do they have any other products in the pipeline?

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Alan Villalon who wrote (5)5/20/1999 6:14:00 PM
From: EyeDrMike
   of 36
 
Nothing that would, IMO, make a material impact on revenues going forward.

Their conventional and disposable line are very good lenses, they just need to gain market share, domestically and internationally, and keep production capacity up to meet demand. They have had problems meeting demand in the past.

Mike

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: EyeDrMike who wrote (6)6/8/1999 2:44:00 PM
From: Alan Villalon
   of 36
 
Anyone know why the bloodbath today? OCLR is down over 6 points (25%) and there isn't any recent news.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Alan Villalon who wrote (7)6/8/1999 2:47:00 PM
From: EyeDrMike
   of 36
 
•1:06 Shares of Ocular Sciences shed nearly one-quarter of their value on trading that was more than 10 times heavier than average. (See other stocks with price and volume gaps.) John Kinnard analyst Richard Leza said he's hearing concerns that the maker of contact lenses (OCLR: news, msgs) will report lower-than-expected sales. He expects Ocular Sciences to show revenue of $47 million, but added some traders say the company may only do $45 million. The South San Francisco-based company declined comment. Shares of Ocular Science fell 6 3/8, or 23 percent, to 20 78.

This said, i bought back in today on the drop, after recently selling based on the introduction of ACUVUE 2 into the marketplace.

At this level, OCLR is a strong buy. IMO.

Mike

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: EyeDrMike who wrote ()6/9/1999 9:44:00 AM
From: Alan Villalon
   of 36
 
How did this leak out. That's BS when people know of news before everyone else. Oh well, I will look to see if management can rebound and recover their earnings growth. Short term bears will pillage this stock.

Wednesday June 9, 9:22 am Eastern Time

Ocular Sciences sees Q2 revs under expectations

LOS ANGELES, Calif, June 9 (Reuters) - Contact lens maker Ocular Sciences (Nasdaq:OCLR - news), whose stock dropped on Tuesday on rumors of an earnings shortfall, said on Wednesday that the company expects revenue in the second quarter to be below expectations.

Ocular Sciences did not give specifics but said ''we currently expect that earnings per share will be in the range of analysts' estimates for the second quarter, on solid, but lower than originally expected revenue.''

Growing investor concern over the company's revenue outlook sliced off more than a quarter of Ocular's value on Tuesday. Shares closed at $19-10/16 after opening at $27.00.

On Wednesday, Ocular said revenues would be impacted by the ''little or no growth'' in the U.S. optical market.

''Continued softness in the U.S. marketplace and the resulting competitive pressures would have an adverse impact on our rate of growth in the second half of the year,'' the company said in a statement, adding it will put more emphasis on international markets.

One analyst, Richard Leza of John G. Kinnard & Co., said he expects the South San Francisco-based company to report second quarter revenues of $45 million and quarterly earnings per share of 39 cents.

Analysts surveyed by First Call expected the company to earn 40 cents a share in the quarter ending June 30.

Share RecommendKeepReplyMark as Last Read


To: EyeDrMike who wrote (8)6/9/1999 8:30:00 PM
From: dragonpawn
   of 36
 
After stock price dropped this much, lawsuits will follow and the
price will drop further.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: dragonpawn who wrote (10)6/9/1999 9:04:00 PM
From: EyeDrMike
   of 36
 
Lawsuits may follow, you can sue a stuffed animal if you have the inclination.

Price dropping further? quite possible , but this company is not going anywhere.

the Acuvue 2 product will be viewed at a "so what" in the eyecare community because a saturated disposable marketplace.

Its going to be hard for JNJ to take market share away from a historically aggressive OSI.

Mike

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: EyeDrMike who wrote (11)6/10/1999 4:28:00 AM
From: dragonpawn
   of 36
 
The laser eye surgery will put OCLR's future in japardy. The stock
price is going no where but down.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: dragonpawn who wrote (12)6/10/1999 8:39:00 AM
From: EyeDrMike
   of 36
 
If everyone in the country decided tomorrow to have laser surgery, it would take 10 years just to build the centers needed.

Hope there is another topic on which you can speak on intelligently.

Share RecommendKeepReplyMark as Last ReadRead Replies (2)


To: EyeDrMike who wrote (13)6/10/1999 10:24:00 AM
From: dragonpawn
   of 36
 
The trend is toward laser eye surgery, contact lens is going down the
drain. It will not happen overnight, but the future is bleak.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)
Previous 10 Next 10